Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05285527 · ClinicalTrials.gov registry record · NA
MiSight 1 Day Safety Post-Approval Study
A NA study of Myopia, sponsored by CooperVision.
- Recruiting
- Registry status
- NA
- Development phase
- 2,400
- Enrollment target
- 20
- Study locations
NCT05285527: Recruiting NA study of Myopia, sponsored by CooperVision.
NCT05285527 is a NA study of Myopia that is actively recruiting participants, run by CooperVision. The registered enrollment target is 2,400 participants, above the 241-participant average among 90 other Myopia trials with a reported enrollment target (896% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05285527, a NA study of Myopia, is actively recruiting participants, sponsored by CooperVision.
- RECRUITING
- Registry status
- NA
- Development phase
- 2,400 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this post-approval study is to confirm the safety of daily disposable soft contact lens wear among the intended patient population for the MiSight 1 Day lens in the US.
Primary Outcome
Incidence of Microbial Keratitis (MK) ≥ 1 mm
Conditions Studied
Interventions
- DEVICE MiSight 1 Day
Study Locations (20)
California
- University of California, Berkeley University Eye Center - Berkeley
- Golden Vision Cupertino Optometry - Cupertino
- Boghossian Vision - Danville
- Iron Horse Optometric Group - Dublin
- Capitol Eye Care Center Optometry - Fremont
- Irvine Eye Physicians and Surgeons Inc - Irvine
- Elsa Pao OD, Inc - Oakland
- Perfect Pair Optometry - San Jose
- Almaden Family Optometric Center - San Jose
Florida
- Planet Vision Eyecare - Lake Worth
- Marino Eye Care - Miami
- Vision Source Oviedo, INC - Oviedo
- Dau Family Eye Care - Saint Johns
- Gulf Coast Eye Center - Sarasota
- Weston Contact Lens Institute LLC - Weston
Arizona
- Experts on Sight LLC. - Gilbert
Arkansas
- Centerton Family Eyecare - Centerton
Colorado
- Children's Eye Physicians - Centennial
Connecticut
- Eye Physicians & Surgeons, PC - Milford
Illinois
- Lurie Childrens - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,400 participants |
| Start Date | 2022-08-15 |
| Est. Completion | 2027-05-30 |
| Phase | NA |
What NCT05285527 shows while recruiting
NCT05285527 is an interventional study that assigns participants to a tested intervention. Its 2,400 participants enrollment target places it among the larger protocols in the corpus, above the 241-participant average among 90 other Myopia trials with a reported enrollment target (896% higher).
The record links to 1 condition, with Myopia appearing as the primary indexed condition, and to 1 intervention - of which MiSight 1 Day is the first listed.
NCT05285527 names 20 study sites across 7 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT05285527 about?
NCT05285527 is a clinical study titled "MiSight 1 Day Safety Post-Approval Study". The purpose of this post-approval study is to confirm the safety of daily disposable soft contact lens wear among the intended patient population for the MiSight 1 Day lens in the US.
What is the current status of trial NCT05285527?
This trial is currently recruiting. It is a NA study. The enrollment target is 2,400 participants. The study started on 2022-08-15. Estimated completion is 2027-05-30.
What conditions does trial NCT05285527 study?
This clinical trial studies the following conditions: Myopia.
What interventions are being tested in trial NCT05285527?
The interventions under investigation include: MiSight 1 Day (DEVICE).
Who is sponsoring clinical trial NCT05285527?
This trial is sponsored by CooperVision, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05285527 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05285527's enrollment target sits among peer trials
2,400 3rd of 90 higher than 88 of 90 other Myopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
RECRUITING · NA
-
Comprehensive Assessment of Multiple Products (CAMP)
RECRUITING · NA
-
Children's Viewing Behavior
RECRUITING · NA
-
Violet Light for the Suppression of Myopia
RECRUITING · NA
-
Measuring Outcomes of LASIK and EVO-ICL in Matched Populations
RECRUITING · NA
-
Wavelength Intervention for Nearsighted Kids
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05185440 · 2,400 participants · NA
Reducing Alcohol Involved Sexual Violence in Higher Education
- NCT05738330 · 2,400 participants · NA
Symptom Monitoring in Hemodialysis
- NCT05833360 · 2,400 participants
Prospective Study of oncRNA Stratification of Cancer by Size and Stage
- NCT05929768 · 2,400 participants · Phase 3
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI